Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes
胰源性糖尿病的病理生理学、流行病学和预防
基本信息
- 批准号:9352327
- 负责人:
- 金额:$ 44.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-28 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAlcoholsAttenuatedBeta CellBlood GlucoseCaliforniaCancer EtiologyCell physiologyCellsCessation of lifeClinicalConflict (Psychology)CountyDefectDesmoplasticDevelopmentDiabetes MellitusDiabetes preventionDiseaseEndocrinologistEndocrinologyEpidemicEpidemiologistEpidemiologyEvaluationExocrine pancreasExocrine pancreatic insufficiencyFatality rateFollow-Up StudiesFoundationsFunctional disorderGastroenterologistGastroenterologyGlucoseGlucose IntoleranceGlucose Metabolism DisordersGoalsHigh Fat DietHormonalImpairmentIncidenceIndividualInflammatoryInjuryInsulinInsulin ResistanceInterventionIntervention StudiesInvestigationIslets of LangerhansKnowledgeLeadLeadershipLocationLos AngelesMalignant neoplasm of pancreasMedical centerMetforminModalityNational Institute of Diabetes and Digestive and Kidney DiseasesNew ZealandNon-Insulin-Dependent Diabetes MellitusObesityPancreasPancreatic PolypeptidePancreatic enzymePancreatitisPathogenesisPathway interactionsPatientsPeripheralPhenotypePhysiologicalPhysiologyPlacebosPlayPopulation HeterogeneityPrediabetes syndromePreventionPreventive therapyProcessPublic HealthPublishingRecurrenceResearchResearch DesignResearch PersonnelRiskRisk FactorsRoleSamplingSmokingSupplementationTestingTimeUnited StatesVulnerable Populationsacute pancreatitisanticancer researcharmblood glucose regulationchronic pancreatitisclinical investigationclinical research sitedata managementdesigndiabetes mellitus therapyethnic diversityexperiencegastric inhibitory polypeptide receptorglucagon-like peptide 1hepatic gluconeogenesisimprovedinflammatory milieuinnovationinsulin secretionintravenous glucose tolerance testisletpatient subsetspreventprospectivepublic health relevanceresponseskills
项目摘要
DESCRIPTION (provided by applicant): This application seeks to establish a Clinical Center (CC) at Cedars-Sinai Medical Center to conduct studies on chronic pancreatitis (CP), diabetes, and pancreatic cancer (RFA-DK-14-027). Drs. Stephen Pandol and Mark Goodarzi (PDs) have assembled a team of gastroenterologists, endocrinologists, physiologists, and epidemiologists who are eager to collaborate in the Consortium in translational pancreatic research. Aside from a track record in clinical investigation and prospective follow-up studies that are the foundation for the proposed CC, our location in Los Angeles County (>9 million inhabitants) affords the Consortium research opportunities in diverse populations through our clinical partners at UCLA and other large medical centers in the region. We have also partnered with productive pancreatology colleagues from Auckland (New Zealand). The proposed studies will elucidate the mechanisms underlying glucose intolerance in CP. Pancreatogenic diabetes (i.e., Type 3c diabetes, T3cDM) develops in most individuals with CP. The risk for pancreatic cancer in patients with both pancreatitis and diabetes is increased 33-fold. Prevention of pancreatitis progression and diabetes (and thus pancreatic cancer) is a critical goal of the Consortium. The following outlines study aims that will be proposed to the Steering Committee once the Consortium is implemented: Aim 1. Test the hypothesis that chronic pancreatitis patients with prediabetes have insulin resistance as well as impaired insulin secretion. Patients with and without CP and with and without prediabetes (4 groups) will undergo the frequently-sampled intravenous glucose tolerance test and mixed meal tolerance tests to characterize insulin resistance, insulin secretion, insulin clearance; and incretin and islet hormonal responses. In focusing on prediabetes, this Aim will identify early defects that predispose to T3cDM. Aim 2. Test the hypothesis that pancreatic enzyme insufficiency in chronic pancreatitis leads to attenuated incretin responses and consequent deficient insulin secretion. The subjects from Aim 1 who have CP and prediabetes will be treated with 2 weeks of pancreatic enzyme supplementation (PES), followed by a repeat physiologic evaluation. It is anticipated that PES will result in augmented incretin responses to a meal, resulting in improved insulin secretion and reduction in glucose levels. Aim 3. Test the hypothesis that metformin treatment will prevent development of diabetes in patients with acute recurrent and chronic pancreatitis. The ability of metformin to prevent Type 3c diabetes is unknown. We will conduct a diabetes prevention study of metformin versus placebo in these patients. Research in CP and pancreatic cancer research requires diverse leadership and multiple clinical sites. We have assembled experts for our CC with skills not always addressing the proposed Aims in recognition of the broad scope of experience and expertise needed to optimize the Consortium's potential. We are committed to interaction with the NIDDK/NCI, the other CCs, and the Coordination and Data Management Center.
描述(由申请人提供):本申请旨在在Cedars-Sinai Medical Center建立临床中心(CC),以开展慢性胰腺炎(CP)、糖尿病和胰腺癌研究(RFA-DK-14 - 027)。Stephen Pandol博士和Mark Goodarzi博士(PD)组建了一个由胃肠病学家,内分泌学家,生理学家和流行病学家组成的团队,他们渴望在转化胰腺研究的联盟中合作。除了临床研究和前瞻性随访研究的跟踪记录是拟议CC的基础之外,我们在洛杉矶县(> 900万居民)的位置通过我们在加州大学洛杉矶分校和该地区其他大型医疗中心的临床合作伙伴为联盟在不同人群中提供研究机会。我们还与来自奥克兰(新西兰)的富有成效的胰腺病学同事合作。这些研究将有助于阐明CP葡萄糖耐受不良的机制。胰源性糖尿病(即,3c型糖尿病(T3cDM)在大多数CP患者中发展。同时患有胰腺炎和糖尿病的患者患胰腺癌的风险增加了33倍。预防胰腺炎进展和糖尿病(以及胰腺癌)是该联盟的关键目标。以下概述了一旦联盟实施将向指导委员会提出的研究目标:目标1。检验慢性胰腺炎伴糖尿病前期患者存在胰岛素抵抗和胰岛素分泌受损的假设。患有和不患有CP的患者以及患有和不患有前驱糖尿病的患者(4组)将接受频繁采样的静脉内葡萄糖耐量试验和混合餐耐量试验,以表征胰岛素抵抗、胰岛素分泌、胰岛素清除以及肠促胰岛素和胰岛激素反应。在关注前驱糖尿病时,该目标将确定易患T3cDM的早期缺陷。目标二。检验慢性胰腺炎中胰酶不足导致肠促胰岛素反应减弱和胰岛素分泌不足的假设。目标1中患有CP和前驱糖尿病的受试者将接受2周的胰酶补充(PES)治疗,然后重复进行生理学评价。预计PES将导致对膳食的肠促胰岛素反应增强,从而改善胰岛素分泌并降低葡萄糖水平。目标3。验证二甲双胍治疗可预防急性复发性和慢性胰腺炎患者发生糖尿病的假设。二甲双胍预防3c型糖尿病的能力尚不清楚。我们将在这些患者中进行二甲双胍与安慰剂的糖尿病预防研究。CP和胰腺癌研究需要多样化的领导和多个临床研究中心。我们已经为我们的CC召集了专家,他们的技能并不总是解决拟议的目标,这是因为我们认识到优化联盟潜力所需的广泛经验和专业知识。我们致力于与NIDDK/NCI、其他CC以及协调和数据管理中心进行互动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark Goodarzi其他文献
Mark Goodarzi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark Goodarzi', 18)}}的其他基金
Southern California Clinical Center of the Type 1 Diabetes in Acute Pancreatitis Consortium
南加州 1 型糖尿病急性胰腺炎联盟临床中心
- 批准号:
10670168 - 财政年份:2020
- 资助金额:
$ 44.58万 - 项目类别:
Southern California Clinical Center of the Type 1 Diabetes in Acute Pancreatitis Consortium
南加州 1 型糖尿病急性胰腺炎联盟临床中心
- 批准号:
10461111 - 财政年份:2020
- 资助金额:
$ 44.58万 - 项目类别:
Southern California Clinical Center of the Type 1 Diabetes in Acute Pancreatitis Consortium
南加州 1 型糖尿病急性胰腺炎联盟临床中心
- 批准号:
10264920 - 财政年份:2020
- 资助金额:
$ 44.58万 - 项目类别:
Impact of the gut microbiome and diet on change in insulin homeostasis and cardiometabolic risk
肠道微生物组和饮食对胰岛素稳态变化和心脏代谢风险的影响
- 批准号:
9924526 - 财政年份:2017
- 资助金额:
$ 44.58万 - 项目类别:
Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer
慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心
- 批准号:
10657640 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer
慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心
- 批准号:
10263513 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer
慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心
- 批准号:
10447160 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes
胰源性糖尿病的病理生理学、流行病学和预防
- 批准号:
9150584 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative Supplement
胰源性糖尿病的病理生理学、流行病学和预防 - 行政补充
- 批准号:
9987256 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer
慢性胰腺炎、糖尿病和胰腺癌研究联盟大洛杉矶临床中心
- 批准号:
10252045 - 财政年份:2015
- 资助金额:
$ 44.58万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 44.58万 - 项目类别:
Research Grant